James Helliwell, CEO of Eupraxia said "We believe EP-104IAR has the potential to transform the treatment paradigm for this condition by offering a favorable safety profile for chronic therapy, including in diabetic patients who make up one third of OA patients. The Phase 2b SPRINGBOARD study met its primary and key secondary endpoints, showing a clinically and statistically meaningful impact on pain, while also demonstrating that EP-104IAR has an encouraging safety profile. In combination with our pre-clinical and MRI results, these data suggest a potential best-in-class candidate in terms of managing cartilage health."
- EPRX Dashboard
- Financials
- Filings
- Patents
-
Article
Eupraxia Reports Upcoming Presentations At Osteoarthritis Research Society International World Congress 2024
Company Profile
Thu. 11 Apr 2024, 7:13am ET
Benzinga
News